• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    2/14/24 6:05:17 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OMER alert in real time by email
    SC 13G/A 1 demop20240213_sc13ga.htm SCHEDULE 13G/A demop20240213_sc13ga.htm

     

     


     

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

     

     

     

    SCHEDULE 13G/A

     

     

     

     

    Under the Securities Exchange Act of 1934

     

     

    (Amendment No. 14)*

     

     

     

     

    OMEROS CORPORATION


    (Name of Issuer)

     

     

                                                                        Common Stock, $0.01 par value


    (Title of Class of Securities)

     

     

    682143 102


    (CUSIP Number)

     

     

    December 31, 2023


    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     [ ] Rule 13d-1(b)

     

    [ ] Rule 13d-1(c)

     

    [ x ] Rule 13d-1(d)

     

     

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

         

    CUSIP No. 682143 102

    (1)

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Gregory A. Demopulos, M.D.

     

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)

     

    (b)

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    United States

           

             Number of

                Shares

    (5)

    Sole Voting Power

     

    5,704,061

            Beneficially

              Owned by

    Each

    (6)

    Shared Voting Power

     

    0

              Reporting

                Person

                  With

    (7)

    Sole Dispositive Power

     

    5,704,061

     

    (8)

    Shared Dispositive Power

     

    0

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,704,061

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]

     

    (See Instructions)

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    8.80%

    (12)

    Type of Reporting Person (See Instructions)

     

    IN

     

     Item 1.

     

     

     

    (a)

    Name of Issuer

     

    OMEROS CORPORATION

     

     

    (b)

    Address of Issuer's Principal Executive Offices

     

    201 Elliott Avenue West

    Seattle, Washington, 98119

     

     

    Item 2.

     

     

     

    (a)

    Name of Person Filing

     

    Gregory A. Demopulos, M.D.

     

     

    (b)

    Address of Principal Business Office or, if none, Residence

     

    201 Elliott Avenue West

    Seattle, WA 98119

     

     

    (c)

    Citizenship

     

    United States

     

     

    (d)

    Title of Class of Securities

     

    Common Stock, $0.01 par value

     

     

    (e)

    CUSIP Number

     

    682143 102

     

     

     Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

     

    (a)

    [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

     

    (b)

    [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

     

    (c)

    [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

     

    (d)

    [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

     

    (e)

    [ ] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

    (f)

    [ ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

    (g)

    [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

    (h)

    [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

    (i)

    [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

    (j)

    [ ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

    Item 4.

     

     

     

    (a)

    Amount beneficially owned:

     

    5,704,061 (includes 3,677,075 shares of common stock that Dr. Demopulos has the right to acquire from the issuer within 60 days of December 31, 2023 pursuant to the exercise of option awards)

     

     

    (b)

    Percent of class:

     

    8.80% (based on shares outstanding as of December 31, 2023)

     

     

    (c)

    Number of shares as to which the person has:

     

     

    (i)

    Sole power to vote or to direct the vote

     

    5,704,061

     

     

    (ii)

    Shared power to vote or to direct the vote

     

    0

     

     

    (iii)

    Sole power to dispose or to direct the disposition of

     

    5,704,061

     

     

    (iv)

    Shared power to dispose or to direct the disposition of

     

    0

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

     

    Item 10. Certification.

     

     

     

    SIGNATURES

     

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

                                                                                                                                                                                                                                             

     

     

     

     

     

     

     

     

     Date: February 14, 2024 

    By:

    /s/  Gregory A. Demopulos

     

     

     

     Name: Gregory A. Demopulos

     

     

     

     

     

     

                                                                                                                                                                                                                                                                                                       

     

     

     
    Get the next $OMER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMER

    DatePrice TargetRatingAnalyst
    6/10/2025$9.00Buy
    H.C. Wainwright
    12/23/2024$36.00Buy
    D. Boral Capital
    11/14/2024$9.00Buy
    Rodman & Renshaw
    12/8/2022$12.00 → $2.00Buy → Neutral
    UBS
    11/8/2022$8.00 → $3.00Neutral → Underperform
    BofA Securities
    6/8/2022$12.00 → $4.00Buy → Neutral
    BofA Securities
    10/19/2021$19.00 → $12.00Buy
    HC Wainwright & Co.
    10/8/2021Neutral → Underweight
    JP Morgan
    More analyst ratings

    $OMER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Finance & CAO Borges David J. sold $750,915 worth of shares (60,000 units at $12.52) and exercised 30,000 shares at a strike of $3.06, closing all direct ownership in the company (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    1/14/26 5:25:24 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO & President Demopulos Gregory A Md gifted 600,000 shares and received a gift of 600,000 shares, decreasing direct ownership by 30% to 1,426,986 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    10/15/25 7:16:04 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman, CEO & President Demopulos Gregory A Md

    4 - OMEROS CORP (0001285819) (Issuer)

    7/1/25 5:32:34 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omeros Announces First Commercial Sales of YARTEMLEA®

    — Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ:OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpatient settings. YARTEMLEA is the first and only approved therapy for

    1/27/26 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

    – Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno

    12/24/25 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Omeros Corporation

    SCHEDULE 13G - OMEROS CORP (0001285819) (Subject)

    1/30/26 2:19:55 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - OMEROS CORP (0001285819) (Filer)

    1/7/26 5:15:49 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - OMEROS CORP (0001285819) (Filer)

    12/29/25 6:08:56 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $OMER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Omeros with a new price target

    H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    6/10/25 8:09:22 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Omeros with a new price target

    D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00

    12/23/24 7:27:28 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Omeros with a new price target

    Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    11/14/24 7:47:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/21/23 8:11:35 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/17/23 9:46:20 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Leadership Updates

    Live Leadership Updates

    View All

    Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

    Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch

    10/19/23 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/24 2:47:02 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    2/14/24 6:05:17 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Omeros Corporation

    SC 13G - OMEROS CORP (0001285819) (Subject)

    2/13/24 5:12:07 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Financials

    Live finance-specific insights

    View All

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

    – Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno

    12/24/25 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

    Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wil

    11/11/25 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care